Overview

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The primary goal of this study is to determine if adding PET-directed local therapy improves disease control compared to standard systemic therapy alone in Veterans with oligorecurrent prostate cancer on PET/CT. The investigators will conduct a multi-institutional phase II/III randomized trial comparing SST with or without PET-directed local therapy using radiation or surgery to all metastases and if a local recurrence is present.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

VA Office of Research and Development

Treatments:

Bicalutamide
Docetaxel
Flutamide
Goserelin
Leuprolide
Methylprednisolone
Nilutamide
Prednisone
Triptorelin Pamoate